AC Immune SA Stock News
$2.43
2.10%
Nasdaq,
Sep 12, 10:00 pm CET
AC Immune SA Stock News
Neutral
GlobeNewsWire
●
about one month ago
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson's disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 Vac...
Neutral
GlobeNewsWire
●
5 months ago
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases Positive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson's disease (PD) Additiona...
Neutral
GlobeNewsWire
●
6 months ago
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
Neutral
GlobeNewsWire
●
6 months ago
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) showcasing the diver...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
